Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA · Entity 3063 | EVP, Europe Commercial | May 05, 2026 | May 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
TEVA PHARMACEUTICAL INDUSTRIES LTD
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 55,755 |
Reported balance
After 2026-05-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-05 · Sale · Disposed 30,000 · Balance 55,755 F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. |
Filing footnotes · ownership attribution and instrument terms
F1: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2018 Filed Mar 14, 2018 20:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 714 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-019556 · doc4.xml · derivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 715 Underlying: Ordinary Shares · 714 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on March 12, 2015, with 714 vesting on March 12, 2018 and 715 vesting on March 12, 2019. F4 · derivative.expiration_date: Restricted share units were granted on March 12, 2015, with 714 vesting on March 12, 2018 and 715 vesting on March 12, 2019. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 714 | $19.50 | $13,921.57 |
DisclosureSEC source: 0001209191-18-019556 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $19.49 to $19.5107, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| March 12, 2018 Filed Mar 14, 2018 20:23 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 714 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-019556 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | SaleOrdinary Shares | 1,108 | $19.28 | $21,362.24 |
DisclosureSEC source: 0001209191-18-017197 · doc4.xml · nonDerivative · entry 3 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 05, 2018 Filed Mar 6, 2018 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Tax withholdingOrdinary Shares | 990 | $19.28 | $19,087.20 |
DisclosureSEC source: 0001209191-18-017197 · doc4.xml · nonDerivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,108 F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionRestricted Share Units · Derivative | 2,098 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-017197 · doc4.xml · derivative · entry 4 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,297 Underlying: Ordinary Shares · 2,098 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F3 · derivative.exercise_date: Restricted share units were granted on March 3, 2017, with 2,098 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 2,101 vesting on March 3, 2021. F3 · derivative.expiration_date: Restricted share units were granted on March 3, 2017, with 2,098 vesting on each of March 3, 2018, March 3, 2019 and March 3, 2020 and 2,101 vesting on March 3, 2021. F1 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| March 03, 2018 Filed Mar 6, 2018 21:08 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | Exercise / conversionOrdinary Shares | 2,098 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-017197 · doc4.xml · nonDerivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. F2 · price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:15 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantRestricted Share Units · Derivative | 39,405 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-18-009180 · doc4.xml · derivative · entry 2 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,405 Underlying: Ordinary Shares · 39,405 shares Expires not disclosed F3 · derivative.exercise_price: Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. F4 · derivative.exercise_date: Restricted share units were granted on February 9, 2018, with 13,135 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F4 · derivative.expiration_date: Restricted share units were granted on February 9, 2018, with 13,135 vesting on each of February 9, 2020, February 9, 2021 and February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
| February 09, 2018 Filed Feb 12, 2018 21:15 UTC | TEVA PHARMACEUTICAL INDUSTRIES LTD TEVA · Entity 3063 | GrantStock Options (right to buy) · Derivative | 100,457 | $0.00 Strike: $18.61 | $0.00 |
DisclosureSEC source: 0001209191-18-009180 · doc4.xml · derivative · entry 1 Daniell Richard · CIK 0001726096 · Exec. VP, European Commercial 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,457 Underlying: Ordinary Shares · 100,457 shares Expires 2028-02-08 F1 · derivative.exercise_date: Stock options were granted on February 9, 2018, with 33,485 vesting on each of February 9, 2020 and February 9, 2021 and 33,487 vesting on February 9, 2022. F2 · derivative.underlying: The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.